MX2023008075A - Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre. - Google Patents
Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.Info
- Publication number
- MX2023008075A MX2023008075A MX2023008075A MX2023008075A MX2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage regimens
- antibodies
- dendritic cell
- cell antigen
- pharmaceutical compositions
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 abstract 2
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 abstract 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan formulaciones y regímenes de dosificación de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre (BDCA2). Estas formulaciones y regímenes de dosificación se usan en el tratamiento de trastornos asociados al BDCA2 tales como el lupus eritematoso sistémico, lupus eritematoso cutáneo y lupus eritematoso discoide, así como el síndrome de liberación de citocinas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008075A true MX2023008075A (es) | 2023-07-18 |
Family
ID=58672794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012945A MX2018012945A (es) | 2016-04-28 | 2017-04-27 | Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. |
| MX2023008075A MX2023008075A (es) | 2016-04-28 | 2018-10-23 | Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012945A MX2018012945A (es) | 2016-04-28 | 2017-04-27 | Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190284281A1 (es) |
| EP (1) | EP3448425A1 (es) |
| JP (3) | JP7045327B2 (es) |
| KR (3) | KR102366547B1 (es) |
| CN (2) | CN109475623B (es) |
| AU (2) | AU2017258191B2 (es) |
| BR (1) | BR112018072125A2 (es) |
| CA (1) | CA3022116A1 (es) |
| CO (1) | CO2018012506A2 (es) |
| EA (1) | EA201892443A1 (es) |
| IL (1) | IL262514A (es) |
| MA (1) | MA44763A (es) |
| MX (2) | MX2018012945A (es) |
| PH (1) | PH12018502278A1 (es) |
| WO (1) | WO2017189827A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019040671A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| CN116963716A (zh) * | 2020-12-03 | 2023-10-27 | 渤健马萨诸塞州股份有限公司 | 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法 |
| WO2023017936A1 (ko) | 2021-08-09 | 2023-02-16 | 주식회사 인벤테라제약 | 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| TW202432188A (zh) * | 2022-12-28 | 2024-08-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體－藥物偶聯物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE030579T2 (en) * | 2003-04-04 | 2017-05-29 | Genentech Inc | High Concentration Antibody And Protein Products |
| DK2928923T3 (da) * | 2012-12-10 | 2020-02-17 | Biogen Ma Inc | Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf |
-
2017
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active IP Right Grant
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Application Discontinuation
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Application Discontinuation
- 2017-04-27 BR BR112018072125-5A patent/BR112018072125A2/pt unknown
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en active Application Filing
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
-
2018
- 2018-10-22 IL IL262514A patent/IL262514A/en unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475623A (zh) | 2019-03-15 |
| AU2017258191B2 (en) | 2024-06-13 |
| CN116850282A (zh) | 2023-10-10 |
| JP7045327B2 (ja) | 2022-03-31 |
| CN109475623B (zh) | 2023-05-26 |
| KR20190002563A (ko) | 2019-01-08 |
| WO2017189827A1 (en) | 2017-11-02 |
| JP2019520316A (ja) | 2019-07-18 |
| CO2018012506A2 (es) | 2018-12-14 |
| AU2024203240A1 (en) | 2024-06-13 |
| CA3022116A1 (en) | 2017-11-02 |
| EP3448425A1 (en) | 2019-03-06 |
| EA201892443A1 (ru) | 2019-04-30 |
| JP2024038308A (ja) | 2024-03-19 |
| US20190284281A1 (en) | 2019-09-19 |
| PH12018502278A1 (en) | 2019-09-09 |
| KR20240033168A (ko) | 2024-03-12 |
| JP2022084782A (ja) | 2022-06-07 |
| BR112018072125A2 (pt) | 2019-03-19 |
| AU2017258191A1 (en) | 2018-11-15 |
| KR20220028150A (ko) | 2022-03-08 |
| IL262514A (en) | 2018-12-31 |
| MX2018012945A (es) | 2019-03-06 |
| KR102366547B1 (ko) | 2022-02-23 |
| MA44763A (fr) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502278A1 (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| PH12020500238A1 (en) | Cytokine conjugates for the treatment of proliferative and infectious diseases | |
| PH12017500803A1 (en) | Anti-pd-1 antibodies | |
| MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| WO2016105542A3 (en) | Nanoparticle compositions and methods for immunotherapy | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MA40539A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicaments | |
| PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| WO2016004213A3 (en) | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them | |
| MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2019015071A (es) | Composiciones y metodos para tratar tauopatias. | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib |